Cerity Partners
NVAX icon

Cerity Partners’s Novavax NVAX Stock Holding History

Cerity Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509K Buy
+54,042
New +$484K ﹤0.01% 2411
2021
Q2 		– Sell
-3,350
Closed -$607K – 729
2021
Q1 		$607K Hold
3,350
– – 0.01% 413
2020
Q4 		$374K Buy
+3,350
New +$356K 0.01% 466
2019
Q1 		– Sell
-3,158
Closed -$116K – 560
2018
Q4 		$116K Buy
3,158
+1,066
+51% +$41.3K 0.01% 499
2018
Q3 		$79K Buy
+2,092
New +$58.9K 0.01% 525

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Cerity Partners's NVAX Position: Q2 2026 in Review

Cerity Partners opened a new position in Novavax (NVAX) in Q2 2026: 54,042 shares worth $509K. The stake represents ﹤0.01% of the portfolio and ranks #2411 among its holdings. This is a return to the name: Cerity Partners previously reported a position in NVAX as recently as Q1 2021.

Cerity Partners first reported a position in NVAX in Q3 2018 and has held it in 5 quarters since. The position peaked at $607K in Q1 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Cerity Partners held 54,042 shares of Novavax worth $509K as of Q2 2026.
  • Novavax was a new Cerity Partners position in Q2 2026.
  • Novavax made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2411 holding.
  • Cerity Partners first reported a position in Novavax in Q3 2018 and has held it in 5 quarters since.
  • Cerity Partners's Novavax position peaked at $607K in Q1 2021.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.